Literature DB >> 10633458

Pathogenesis of secondary hyperparathyroidism.

E Slatopolsky1, A Brown, A Dusso.   

Abstract

Secondary hyperparathyroidism is a universal complication in patients with chronic renal failure. Hyperplasia of the parathyroid glands is typically seen in these patients. In early renal failure, alteration in vitamin metabolism, decreased levels of calcitriol and moderate decreases in ionized calcium may allow greater synthesis and secretion of PTH. As the disease progresses, there is a decrease in the number of vitamin D receptors (VDR) and calcium receptors (CaR). The decreased number of VDR and CaR makes the parathyroid glands more resistant to calcitriol and calcium. Phosphorus induces hyperplasia of the parathyroid glands independent of calcium and calcitriol, and by a post-transcriptional mechanism increases PTH synthesis and secretion. Experimental work in uremic rats demonstrated that if the animals are fed a high-phosphorus diet, they not only developed secondary hyperparathyroidism but parathyroid cell hyperplasia. If the diet is then reduced in phosphorus, the levels of PTH return to normal. However, the parathyroid cell hyperplasia persists and no apoptosis is seen. Thus, the control of the three most important factors, calcium, calcitriol and phosphorus, is critical to prevent the development of secondary hyperparathyroidism and hyperplasia of the parathyroid glands.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10633458     DOI: 10.1046/j.1523-1755.1999.07304.x

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  57 in total

1.  The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis.

Authors:  Naro Ohashi; Toshihiko Uematsu; Satoru Nagashima; Mitsutaka Kanamaru; Akashi Togawa; Akira Hishida; Eiji Uchida; Tadao Akizawa; Shozo Koshikawa
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

Review 2.  Cinacalcet: a pharmacoeconomic review of its use in secondary hyperparathyroidism in end-stage renal disease.

Authors:  Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2011-09       Impact factor: 4.981

Review 3.  Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality.

Authors:  Adriana Dusso; Maria Vittoria Arcidiacono; Jing Yang; Masanori Tokumoto
Journal:  J Steroid Biochem Mol Biol       Date:  2010-03-30       Impact factor: 4.292

Review 4.  Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride.

Authors:  Desmond Padhi; Robert Harris
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 5.  New therapies: calcimimetics, phosphate binders and vitamin D receptor activators.

Authors:  Jorge B Cannata-Andía; Minerva Rodriguez-García; Pablo Román-García; Diego Tuñón-le Poultel; Francisco López-Hernández; Diego Rodríguez-Puyol
Journal:  Pediatr Nephrol       Date:  2010-02-12       Impact factor: 3.714

6.  Effects of calcium carbonate, sevelamer hydrochloride or pantoprazole on the pharmacokinetics of cinacalcet.

Authors:  Desmond Padhi; Robert Harris; John T Sullivan
Journal:  Clin Drug Investig       Date:  2014-08       Impact factor: 2.859

7.  CYP2D6, GST-M1 and GST-T1 enzymes: expression in parathyroid gland and association with the parathyroid hormone concentration during early renal replacement therapy.

Authors:  Feng-Xiang Yan; M Chris Langub; Mark A Ihnen; Carlton Hornung; Erkki Juronen; Mary K Rayens; Wei-Min Cai; Peter J Wedlund; Paolo Fanti
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

8.  Risk factors associated with secondary hyperparathyroidism in patients with chronic kidney disease.

Authors:  Yudan Wei; Jing Lin; Fan Yang; Xiujiang Li; Yue Hou; Ronghua Lu; Xiaonv Shi; Zhi Liu; Yujun Du
Journal:  Exp Ther Med       Date:  2016-06-08       Impact factor: 2.447

9.  Allosteric modulation of the calcium-sensing receptor.

Authors:  Anders A Jensen; Hans Bräuner-Osborne
Journal:  Curr Neuropharmacol       Date:  2007-09       Impact factor: 7.363

10.  Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol.

Authors:  Ditte Hansen; Lisbet Brandi; Knud Rasmussen
Journal:  BMC Nephrol       Date:  2009-09-24       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.